Joseph Cowan - Nice Independent Director
| NICE Stock | ILA 65,360 1,550 2.32% |
Director
Mr. Joseph L. Cowan serves as Independent Director at Nice Ltd. He is a member of the Compensation and Mergers and Acquisitions committees. His work experience includes the following roles Chief Executive Officer and Director at Epicor, President at DataDirect Networks, Inc., Director at DataDirect Networks, Inc., Chief Executive Officer and President at Online Resources Corporationration, Operating Executive and Consultant at Vector Capital, Chief Executive Officer at Interwoven Inc., President and Chief Executive Officer at Manugistics Inc. and Manugistics Group Inc., Chief Executive Officer at Baan Co. NV, Chief Executive Officer at Avantis GOB NV, Director at Interwoven Inc., Online Resources Corporationrationration, Manugistics Group Inc. and Blackboard Inc. and at various additional companies since 2013.
| Age | 70 |
| Tenure | 11 years |
| Phone | (972) 9 775 3151 |
| Web | www.nice.com |
Nice Management Efficiency
The company has return on total asset (ROA) of 0.0433 % which means that it generated a profit of $0.0433 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0863 %, meaning that it generated $0.0863 on every $100 dollars invested by stockholders. Nice's management efficiency ratios could be used to measure how well Nice manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Ehood Nisan | Elbit Systems | 51 | |
| Rosemary Crane | Teva Pharmaceutical Industries | 59 | |
| Dov Ninveh | Elbit Systems | 71 | |
| Yuli Tamir | Elbit Systems | 65 | |
| Yoram BenZeev | Elbit Systems | 74 | |
| Rina Baum | Elbit Systems | 73 | |
| JeanMichel Halfon | Teva Pharmaceutical Industries | 67 | |
| Gerald Lieberman | Teva Pharmaceutical Industries | 72 | |
| Avraham Guzman | Tower Semiconductor | 79 | |
| Alex Kornhauser | Tower Semiconductor | 71 | |
| Perry Nisen | Teva Pharmaceutical Industries | 63 | |
| Kalman Kaufman | Tower Semiconductor | 72 | |
| Roberto Mignone | Teva Pharmaceutical Industries | 47 | |
| Ilan Flato | Tower Semiconductor | 61 | |
| Dana Gross | Tower Semiconductor | 51 | |
| Nechemia Peres | Teva Pharmaceutical Industries | 60 | |
| Yehoshua Gleitman | Elbit Systems | 69 | |
Management Performance
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0433 |
Nice Leadership Team
Elected by the shareholders, the Nice's board of directors comprises two types of representatives: Nice inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nice. The board's role is to monitor Nice's management team and ensure that shareholders' interests are well served. Nice's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nice's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Beth Gaspich, Chief Financial Officer | ||
| Yaron Hertz, President-NICE Americas | ||
| John OHara, President-NICE EMEA | ||
| Craig Costigan, Chief Executive Officer, NICE Actimize | ||
| Joseph Cowan, Independent Director | ||
| Dan Falk, Independent Director | ||
| Christopher Wooten, Executive Vice President Surveillance | ||
| Yehoshua Ehrlich, Independent Director | ||
| Rimon BenShaoul, Independent Director | ||
| Eran Liron, Executive Vice President - Marketing & Corporate Development | ||
| Zehava Simon, Independent Director | ||
| Shiri Neder, Executive Vice President of Human Resources | ||
| Yocheved Dvir, Independent Director | ||
| Barak Eilam, Chief Executive Officer | ||
| David Kostman, Independent Chairman of the Board | ||
| Leo Apotheker, Independent Director | ||
| Tali MirskyLachman, Corporate Vice President, General Counsel, Corporate Secretary | ||
| Barry Cooper, Executive Vice President - Professional Services and Customer Support | ||
| Paul Jarman, Chief Executive Officer, NICE inContact |
Nice Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nice a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0433 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 40.59 B | |||
| Shares Outstanding | 63.53 M | |||
| Shares Owned By Institutions | 12.10 % | |||
| Price To Book | 4.30 X | |||
| Price To Sales | 20.69 X | |||
| Revenue | 1.92 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Nice Stock
Nice financial ratios help investors to determine whether Nice Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nice with respect to the benefits of owning Nice security.